Skip to main content

Advertisement

SpringerLink
Log in

Pityriasis Rubra Pilaris: An Updated Review of Clinical Presentation, Etiopathogenesis, and Treatment Options

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Pityriasis rubra pilaris (PRP) is a rare papulosquamous reaction pattern with a significant impact on quality of life. Type I PRP is the most common PRP variant, presenting as erythematous papules emerging in a follicular distribution and later coalescing into plaques with characteristic islands of sparing; histologically, an alternating pattern of orthokeratosis and parakeratosis is considered the hallmark of PRP (checkerboard hyperkeratosis). Other PRP variants (types II–V) differ in their age of onset and clinical presentation. Type VI PRP is a rare PRP subtype associated with human immunodeficiency virus infection and is occasionally associated with diseases of the follicular occlusion tetrad. Caspase recruitment domain family, member 14 (CARD14)-associated papulosquamous eruption and facial discoid dermatitis are newly described disease states that have an important clinical overlap with PRP, creating shared conundrums with respect to diagnosis and treatment. The etiology inciting PRP often remains uncertain; PRP has been suggested to be associated with infection, malignancy, or drug/vaccine administration in some cases, although these are based on case reports and causality has not been established. Type V PRP is often due to inborn CARD14 mutations. Furthermore, recent literature has identified interleukin-23/T-helper-17 cell axis dysregulation to be a major mediator of PRP pathogenesis, paving the way for mechanism-directed therapy. At present, high-dose isotretinoin, ixekizumab, and secukinumab are systemic agents supported by single-arm prospective studies; numerous other agents have also been trialed for PRP, with variable success rates. Here, we discuss updates on clinical manifestations, present new insights into etiopathogenesis, and offer a survey of recently described therapeutic options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Tarral C. General psoriasis. Desquamation from the parts covered with hair. Theor Pract Treatise Dis Skin. 1835;2:648–9.

    Google Scholar 

  2. Devergie M. Pityriasis pilaris, maladie de peau non decrite par les dermatologistes. Gaz Hebd Med Chir. 1856;3:197–201.

    Google Scholar 

  3. Besnier E. Observations pour servir à l’histoire clinique du pityriasis rubra pilaire. Ann Derm Syph Ser. 1889;10.

  4. Wang D, Chong VC-L, Chong W-S, Oon HH. A review on pityriasis rubra pilaris. Am J Clin Dermatol. 2018;19:377–90.

    Article  PubMed  Google Scholar 

  5. Sehgal VN, Jain MK, Mathur RP. Pityriasis rubra pilaris in Indians. Br J Dermatol. 1989;121:821–2.

    Article  CAS  PubMed  Google Scholar 

  6. Griffiths WA. Pityriasis rubra pilaris. Clin Exp Dermatol. 1980;5:105–12.

    Article  CAS  PubMed  Google Scholar 

  7. Ross NA, Chung H-J, Li Q, Andrews JP, Keller MS, Uitto J. Epidemiologic, clinicopathologic, diagnostic, and management challenges of pityriasis rubra pilaris: a case series of 100 patients. JAMA Dermatol. 2016;152:670–5.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Marrouche N, Kurban M, Kibbi A-G, Abbas O. Pityriasis rubra pilaris: clinicopathological study of 32 cases from Lebanon. Int J Dermatol. 2014;53:434–9.

    Article  PubMed  Google Scholar 

  9. Ghatnekar S, Shah N, Min MS, Mazori DR, LaChance AH, Vleugels RA, et al. Clinical features and eosinophilia in pityriasis rubra pilaris: a multicenter cohort. J Am Acad Dermatol. 2022;86:907–9.

    Article  PubMed  Google Scholar 

  10. Halper K, Wright B, Maloney NJ, Kim MM, Ravi V, Worswick S, et al. Characterizing disease features and other medical diagnoses in patients with pityriasis rubra pilaris. JAMA Dermatol. 2020;156:1373–4.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Plante JG, Aleisa AI, Thiers BH. Pityriasis rubra pilaris in skin of color. Int J Womens Dermatol. 2021;7:207–8.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Sonnex TS, Dawber RP, Zachary CB, Millard PR, Griffiths AD. The nails in adult type 1 pityriasis rubra pilaris: a comparison with Sézary syndrome and psoriasis. J Am Acad Dermatol. 1986;15:956–60.

    Article  CAS  PubMed  Google Scholar 

  13. Ji-Xu A, Lei DK, Maloney NJ, Worswick S. Clinical course, diagnostic patterns, and treatment outcomes in patients with pityriasis rubra pilaris. J Am Acad Dermatol. 2022;87:1450–1.

    Article  PubMed  Google Scholar 

  14. Wong J-Y, Surgenor L, McCourt C. Pityriasis rubra pilaris with erythema gyratum repens-like eruption and resolution with ustekinumab. Clin Exp Dermatol. 2022;47:2300–3.

    Article  PubMed  Google Scholar 

  15. Richey PM, Fairley JA, Stone MS. Transformation from pityriasis rubra pilaris to erythema gyratum repens-like eruption without associated malignancy: a report of 2 cases. JAAD Case Rep. 2018;4:944–6.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Gloor AD, van Rhyn M, Schlapbach C. Erythema gyratum repens-like eruption after anti-IL-17 therapy of pityriasis rubra pilaris. J Eur Acad Dermatol Venereol. 2021;35:e38-40.

    Article  CAS  PubMed  Google Scholar 

  17. Davenport R, Le ST, Gin A, Goh MS, Foley P. Resolving classic pityriasis rubra pilaris, mimicker of erythema gyratum repens. Australas J Dermatol. 2018;59:232–3.

    Article  PubMed  Google Scholar 

  18. Velasco RC, Shao C, Greiling TM. Patient-reported cutaneous signs and symptoms of adult pityriasis rubra pilaris and correlation with quality of life and clinician-reported severity: a cross-sectional study. J Am Acad Dermatol. 2023;S0190–9622(23):02865–7.

    Google Scholar 

  19. Yang C-C, Shih I-H, Lin W-L, Yu Y-S, Chiu H-C, Huang P-H, et al. Juvenile pityriasis rubra pilaris: report of 28 cases in Taiwan. J Am Acad Dermatol. 2008;59:943–8.

    Article  PubMed  Google Scholar 

  20. Allison DS, El-Azhary RA, Calobrisi SD, Dicken CH. Pityriasis rubra pilaris in children. J Am Acad Dermatol. 2002;47:386–9.

    Article  PubMed  Google Scholar 

  21. Gelmetti C, Schiuma AA, Cerri D, Gianotti F. Pityriasis rubra pilaris in childhood: a long-term study of 29 cases. Pediatr Dermatol. 1986;3:446–51.

    Article  CAS  PubMed  Google Scholar 

  22. Piamphongsant T, Akaraphant R. Pityriasis rubra pilaris: a new proposed classification. Clin Exp Dermatol. 1994;19:134–8.

    Article  CAS  PubMed  Google Scholar 

  23. MacGillivray ME, Fiorillo L. Recurrent pityriasis rubra pilaris: a case report. J Cutan Med Surg. 2018;22:624–6.

    Article  PubMed  Google Scholar 

  24. Lambert DG, Dalac S. Nail changes in type 5 pityriasis rubra pilaris. J Am Acad Dermatol. 1989;21:811–2.

    Article  CAS  PubMed  Google Scholar 

  25. Blauvelt A, Nahass GT, Pardo RJ, Kerdel FA. Pityriasis rubra pilaris and HIV infection. J Am Acad Dermatol. 1991;24:703–5.

    Article  CAS  PubMed  Google Scholar 

  26. Miralles ES, Núñez M, De Las Heras ME, Pérez B, Moreno R, Ledo A. Pityriasis rubra pilaris and human immunodeficiency virus infection. Br J Dermatol. 1995;133:990–3.

    Article  CAS  PubMed  Google Scholar 

  27. Nair PA, Sheth N. Atypical adult-onset pityriasis rubra pilaris in an HIV-positive adult male. Indian J Dermatol. 2018;63:522–4.

    PubMed  PubMed Central  Google Scholar 

  28. Kranyak A, Shuler M. Pityriasis rubra pilaris rapidly cleared with ixekizumab in an HIV-positive patient. JAAD Case Rep. 2022;27:55–7.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Williams A, George A, Thomas EA, Koshy JM. Pityriasis rubra pilaris type 6: a case report in an AIDS patient. Indian J Sex Transm Dis AIDS. 2020;41:100–1.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Craiglow BG, Boyden LM, Hu R, Virtanen M, Su J, Rodriguez G, et al. CARD14-associated papulosquamous eruption: a spectrum including features of psoriasis and pityriasis rubra pilaris. J Am Acad Dermatol. 2018;79:487–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Li N, Tao J, Zhang J, Liu Z, Yu P. A novel mutation in a CARD14-associated papulosquamous eruption. Pediatr Dermatol. 2023;40:706–9.

  32. Takeichi T, Terawaki S, Kubota Y, Ito Y, Tanahashi K, Muro Y, et al. A patient with CARD14-associated papulosquamous eruptions showing atopic dermatitis-like features. J Eur Acad Dermatol Venereol. 2021;35:e58–9.

    Article  CAS  PubMed  Google Scholar 

  33. Ko CJ, Heald P, Antaya RJ, Bolognia JL. Facial discoid dermatosis. Int J Dermatol. 2010;49:189–92.

    Article  PubMed  Google Scholar 

  34. Salman A, Tekin B, Berenjian A, Cinel L, Demirkesen C. Facial discoid dermatosis: a further case of a novel entity. J Dermatol. 2015;42:1132–3.

    Article  PubMed  Google Scholar 

  35. Bohdanowicz M, DeKoven JG. Improvement in facial discoid dermatosis with calcipotriol/betamethasone ointment and low-dose acitretin. Clin Exp Dermatol. 2018;43:820–1.

    Article  CAS  PubMed  Google Scholar 

  36. Condal L, Quer A, Ferrándiz C, Bielsa I. Facial discoid dermatosis: an enigmatic disease. Actas Dermosifiliogr (Engl Ed). 2020;S0001–7310(20):30549–54.

    Google Scholar 

  37. Amarnani R, Hughes S, Morris-Jones R, Kanwar AJ, Bunker CB. Persistent facial discoid dermatosis successfully treated with topical calcipotriol. Clin Exp Dermatol. 2022;47:229–31.

    Article  CAS  PubMed  Google Scholar 

  38. Welborn M, Fletcher D, Motaparthi K. Atrophy of sebaceous lobules in facial discoid dermatosis: a link to psoriasis and seborrheic dermatitis? J Cutan Pathol. 2022;49:320–3.

    Article  PubMed  Google Scholar 

  39. Rahmatulla S, Batta K, Tatnall F, Sandhu D, Brown V. Facial discoid dermatosis: a cosmetically disfiguring and challenging condition to treat. Skin Health Dis. 2021;1: e56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Zaladonis AG, Lee JB, Hsu S, Motaparthi K. Facial discoid dermatosis: what is it? Skinmed. 2022;20:174–6.

    PubMed  Google Scholar 

  41. Gan EY, Ng SK, Goh CL, Lee SSJ. Recalcitrant psoriasiform dermatosis of the face: is it related to pityriasis rubra pilaris? J Cutan Pathol. 2018;45:491–7.

    Article  PubMed  Google Scholar 

  42. Rypka KJ, Fulk TS, Afsaneh A, Miller DD, Goldfarb NI. Improvement of facial discoid dermatosis with ustekinumab treatment. JAMA Dermatol. 2022;158:1079–80.

    Article  PubMed  Google Scholar 

  43. Allegue F, Fachal C, Iglesias B, Zulaica A. Facial discoid dermatosis: a new variant of pityriasis rubra pilaris? Actas Dermosifiliogr. 2022;113:728–31.

    Article  CAS  PubMed  Google Scholar 

  44. Davis AE, Raine BE, Swartzman I, Bogner PN, Nazareth M. Rethinking pityriasis rubra pilaris as a paraneoplastic syndrome: two cases of pityriasis rubra pilaris with concomitant underlying malignancy. JAAD Case Rep. 2023;32:90–5.

    Article  PubMed  Google Scholar 

  45. Ji-Xu A, Lei DK, Worswick S, Maloney NJ, Kim MM, Cutler L. Patient and disease characteristics associated with psychiatric symptoms and impaired quality of life in pityriasis rubra pilaris. Br J Dermatol. 2022;187:1024–6.

    Article  PubMed  Google Scholar 

  46. Eastham AB, Tkachenko EY, Femia AN, Pappas-Taffer LK, Rosenbach M, Joyce CJ, et al. Pityriasis rubra pilaris: a study evaluating patient quality of life in 2 populations. J Am Acad Dermatol. 2019;81:638–40.

    Article  PubMed  Google Scholar 

  47. Velasco RC, Cutler B, McCue W, Greiling TM. The comprehensive impact of pityriasis rubra pilaris onphysical symptoms, mental health, and activities ofdaily living: a mixed methods study. JEADV Clin Pract. 2023;2:185–92.

    Google Scholar 

  48. Fania L, Didona D, Pacifico V, Mariotti F, De Luca N, Abeni D, et al. Bullous pemphigoid with hyperkeratosis and palmoplantar keratoderma: three cases. J Dermatol. 2018;45:1135–40.

    Article  PubMed  Google Scholar 

  49. Jha AK, Lallas A, Sonthalia S, Jhakar D, Udayan UK, Chaudhary RKP. Differentiation of pityriasis rubra pilaris from plaque psoriasis by dermoscopy. Dermatol Pract Concept. 2018;8:299–302.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Abdel-Azim NE, Ismail SA, Fathy E. Differentiation of pityriasis rubra pilaris from plaque psoriasis by dermoscopy. Arch Dermatol Res. 2017;309:311–4.

    Article  CAS  PubMed  Google Scholar 

  51. Ko CJ, Milstone LM, Choi J, McNiff JM. Pityriasis rubra pilaris: the clinical context of acantholysis and other histologic features. Int J Dermatol. 2011;50:1480–5.

    Article  PubMed  Google Scholar 

  52. Ring NG, Craiglow BG, Panse G, Antaya RJ, Ashack K, Ashack R, et al. Histopathologic findings characteristic of CARD14-associated papulosquamous eruption. J Cutan Pathol. 2020;47:425–30.

    Article  PubMed  Google Scholar 

  53. Fuchs-Telem D, Sarig O, van Steensel MAM, Isakov O, Israeli S, Nousbeck J, et al. Familial pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet. 2012;91:163–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Spoerri I, Herms S, Eytan O, Sarig O, Heinimann K, Sprecher E, et al. Immune-regulatory genes as possible modifiers of familial pityriasis rubra pilaris: lessons from a family with PRP and psoriasis. J Eur Acad Dermatol Venereol. 2018;32:e389–92.

    Article  CAS  PubMed  Google Scholar 

  55. Akiyama M, Sugiyama-Nakagiri Y, Sakai K, McMillan JR, Goto M, Arita K, et al. Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer. J Clin Invest. 2005;115:1777–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Kobashi H, Ishimoto T, Yamamoto M, Nakajima K, Takeichi T, Akiyama S, et al. A novel missense mutation in the ABCA12 gene in Japanese siblings with congenital ichthyosis erythroderma. Nishinihon J Dermatol. 2019;81:382–6.

    Article  Google Scholar 

  57. Takeichi T, Hamada T, Yamamoto M, Ito Y, Kawaguchi A, Kobashi H, et al. Patients with keratinization disorders due to ABCA12 variants showing pityriasis rubra pilaris phenotypes. J Dermatol. 2023.

  58. Wang M, Zhang S, Zheng G, Huang J, Songyang Z, Zhao X, et al. Gain-of-function mutation of Card14 leads to spontaneous psoriasis-like skin inflammation through enhanced keratinocyte response to IL-17A. Immunity. 2018;49:66-79.e5.

    Article  CAS  PubMed  Google Scholar 

  59. Mellett M, Meier B, Mohanan D, Schairer R, Cheng P, Satoh TK, et al. CARD14 gain-of-function mutation alone is sufficient to drive IL-23/IL-17-mediated psoriasiform skin inflammation in vivo. J Invest Dermatol. 2018;138:2010–23.

    Article  CAS  PubMed  Google Scholar 

  60. Strunck JL, Cutler B, Rajpal B, Kent G, Haynes D, Topham CA, et al. Pityriasis rubra pilaris response to IL-17A inhibition is associated with IL-17C and CCL20 protein levels. J Invest Dermatol. 2022;142:235-9.e1.

    Article  CAS  PubMed  Google Scholar 

  61. Shao S, Chen J, Swindell WR, Tsoi LC, Xing X, Ma F, et al. Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris. JCI Insight. 2021;6: e151911.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Boudreaux BW, Pincelli TP, Bhullar PK, Patel MH, Brumfiel CM, Li X, et al. Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis. Br J Dermatol. 2022;187:650–8.

    Article  CAS  PubMed  Google Scholar 

  63. Haynes D, Reiter T, Velasco R, Chang M, Kulkarni R, Kent G, et al. Pityriasis rubra pilaris transcriptomics implicate T helper 17 signaling and correlate with response to ixekizumab, with distinct gene expression profiles in nonresponders. J Invest Dermatol. 2023;143:501-4.e1.

    Article  CAS  PubMed  Google Scholar 

  64. Filippi F, Patrizi A, Chessa MA, Virdi A, Neri I. A novel presentation of juvenile pityriasis rubra pilaris with possible involvement of bacterial superantigens. J Dtsch Dermatol Ges. 2022;20:335–7.

    PubMed  Google Scholar 

  65. Ishikawa M, Igari S, Hiraiwa T, Hanami Y, Yamamoto T. Pityriasis rubra pilaris significantly improved after treatment for chronic focal infection. Indian J Dermatol. 2022;67:626.

    PubMed  PubMed Central  Google Scholar 

  66. Aromolo IF, Pisapia A, Riva D, Barberi F, Marzano AV, Moltrasio C, et al. COVID-19 induced pityriasis rubra pilaris: a superantigenic disease? J Eur Acad Dermatol Venereol. 2023;37:e26–8.

    Article  PubMed  Google Scholar 

  67. Kadylak D, Barańska-Rybak W. Acute postinfectious pityriasis rubra pilaris as a cutaneous manifestation in COVID-19: a case report and its dermoscopic features. J Eur Acad Dermatol Venereol. 2021;35:e622–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Aguilar-Gamboa FR, Cubas-Alarcon D, Villegas-Chiroque M, Failoc-Rojas VE. Pityriasis rubra pilaris post-infection due COVID-19: case report. Colomb Med (Cali). 2021;52: e7014577.

    PubMed  PubMed Central  Google Scholar 

  69. Mufti A, Lytvyn Y, Maliyar K, Sachdeva M, Yeung J. Drugs associated with development of pityriasis rubra pilaris: a systematic review. J Am Acad Dermatol. 2021;84:1071–81.

    Article  PubMed  Google Scholar 

  70. Goldberger T, Armoni G, Lavie D, Merims S, Maly A, Shreberk-Hassidim R. Pityriasis rubra pilaris induced by PD-1 inhibitor nivolumab. Int J Dermatol. 2021;60:1038–9.

    Article  CAS  PubMed  Google Scholar 

  71. Weber I, Gloss C, Castillo B, Smith E. Ponatinib-associated cutaneous eruptions: a case series and review of clinicopathologic findings. Am J Dermatopathol. 2023;45:64–8.

    Article  PubMed  Google Scholar 

  72. Mongereau M, Hillion B, Fouillard L, Boivin J-F, Gaudron S. Pityriasis rubra pilaris-like reaction induced by a tyrosine kinase inhibitor, the ponatinib. Am J Dermatopathol. 2021;43:394–5.

    Article  PubMed  Google Scholar 

  73. Kamat D, Chatterjee D, Mahajan R. Ponatinib-induced atypical pityriasis rubra pilaris-like rash. Indian J Dermatol Venereol Leprol. 2020;86:688–90.

    Article  PubMed  Google Scholar 

  74. Lahouel M, Gammoudi R, Saidi W, Sriha B, Belajouza C, Denguezli M. Nilotinib-induced pityriasis rubra pilaris: first case report. Dermatol Ther. 2020;33: e14085.

    Article  PubMed  Google Scholar 

  75. Armillas-Lliteras L, Iglesias-Sancho M, Altemir A, Moreno Romero JA. Pityriasis rubra pilaris induced by topical use of imiquimod 5. An Bras Dermatol. 2023;S0365–0596(23):00150–2.

    Google Scholar 

  76. Al-Hage J, Akel R, Kurban M, Abbas O. Plasmacytoid dendritic cells in pityriasis rubra pilaris. Ann Dermatol. 2019;31:87–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Criado PR, Ianhez M, Rocha PS, Miot HA. Pityriasis rubra pilaris (type I) following ChAdOx1 COVID-19 vaccine: a report of two cases with successful treatment with oral isotretinoin. J Eur Acad Dermatol Venereol. 2022;36:e508–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Lladó I, Butrón B, Sampedro-Ruiz R, Fraga J, de Argila D. Pityriasis rubra pilaris after Vaxzevria® COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2021;35:e833–5.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Gambichler T, Scheel CH, Arafat Y, Kautz O, Boms S. Erythrodermic pityriasis rubra pilaris after SARS-CoV-2 vaccination with concomitant COVID-19 infection. J Eur Acad Dermatol Venereol. 2022;36:e675–6.

    Article  CAS  PubMed  Google Scholar 

  80. Zhao P, Rusu CA, Schenck OL. Pityriasis rubra pilaris following COVID-19 vaccination successfully treated with ixekizumab. JAAD Case Rep. 2023;35:52–6.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Liu YA, Dai J, Nagarajan P, Torres-Cabala CA, Aung PP, Prieto VG, et al. Pityriasis rubra pilaris after Moderna COVID-19 vaccination: a case report and literature review. Am J Dermatopathol. 2023;45:185–8.

    Article  PubMed  Google Scholar 

  82. Zhang L-W, Wang W-J, Fu L-X, Lu Y-H, Chen T, Xu R-H. Pityriasis rubra pilaris following inactivated SARS-CoV-2 vaccine (CoronaVac). J Eur Acad Dermatol Venereol. 2023;37:e287–8.

    Article  CAS  PubMed  Google Scholar 

  83. Gamonal SBL, Marques NCV, Pereira HMB, Gamonal ACC. Pityriasis rubra pilaris (type I) following administration of the BNT162b2 mRNA COVID-19 vaccine: successful treatment with ustekinumab and acitretin. Dermatol Ther. 2022;35: e15899.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Hlaca N, Zagar T, Kastelan M, Peternel S, Brajac I, Dujmovic-Hasanbegovic K, et al. Pityriasis rubra pilaris following booster dose of mRNA (Pfizer-BioNTech) COVID-19 vaccine. Dermatol Ther. 2022;35: e15791.

    Article  CAS  PubMed  Google Scholar 

  85. Liu Y-T, Wang S-S. Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID-19 vaccination. Skin Health Dis. 2022;3: e139.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Arora A, Mohta A, Ghiya BC, Kumar JV. Acute postinfectious type III pityriasis rubra pilaris as a cutaneous manifestation in COVID-19: decoding a possible trigger!! J Cosmet Dermatol. 2022;21:3206–7.

    Article  PubMed  Google Scholar 

  87. Wada M, Lee S, Curnow P, Simpson I, Mar A. A case of pityriasis rubra pilaris following AstraZeneca COVID-19 vaccine. JAAD Case Rep. 2022;24:74–7.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Ajebo EM, Howard JD, Anand D, Davis LS. Pityriasis rubra pilaris potentially triggered by messenger RNA-1273 COVID vaccine. JAAD Case Rep. 2022;23:114–6.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Fernández LT, Pérez-Garza DM, delaO-Escamilla A, Yamallel-Ortega LA, Cuellar-Barboza A, Ocampo-Candiani J, et al. Pityriasis rubra pilaris in association with inactivated SARS-CoV-2 vaccine (CoronaVac). Dermatol Ther. 2022;35:e15455.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Sechi A, Pierobon E, Pezzolo E, Germi L, Trevisan G, Zardo D, et al. Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID-19 vaccine. Clin Exp Dermatol. 2022;47:437–40.

    Article  CAS  PubMed  Google Scholar 

  91. Sahni MK, Roy K, Asati DP, Khurana U. An old entity, a new trigger: post COVID-19 vaccine pityriasis rubra pilaris. Int J Risk Saf Med. 2021;32:261–4.

    Article  PubMed  Google Scholar 

  92. Hunjan MK, Roberts C, Karim S, Hague J. Pityriasis rubra pilaris-like eruption following administration of the BNT163b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine. Clin Exp Dermatol. 2022;47:188–90.

    Article  CAS  PubMed  Google Scholar 

  93. Gambichler T. Clinical characteristics of patients with pityriasis rubra pilaris following SARS-CoV-2 vaccination. J Eur Acad Dermatol Venereol. 2023.

  94. Sharma RK, Gupta M, Gulati A. Koebner phenomenon in classic juvenile onset pityriasis rubra pilaris. Indian Dermatol Online J. 2019;10:469–70.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Acar EM, Has S, Kilitci A, Kemeriz F. Circumscribed juvenile pityriasis rubra pilaris (type 4) Koebnerising after a hot water burn: mild disease with maximum Koebner response. Acta Dermatovenerol Croat. 2019;27:47–9.

    PubMed  Google Scholar 

  96. Genovese G, Muratori S, Berti E, Marzano AV. Bullous erythroderma: novel association of pityriasis rubra pilaris with bullous pemphigoid. Clin Exp Dermatol. 2019;44:73–5.

    Article  CAS  PubMed  Google Scholar 

  97. Gasslitter I, Löffler-Ragg J, Schmidt E, Schmuth M, Gruber R. Coincidence of bullous pemphigoid and pityriasis rubra pilaris. Acta Derm Venereol. 2022;102:adv00674.

    Article  PubMed  Google Scholar 

  98. Sugihara N, Kamiya K, Nakano N, Suzuki M, Maekawa T, Murata S, et al. A case of bullous pemphigoid developing after ixekizumab therapy for pityriasis rubra pilaris. J Dermatol. 2023;50:e185–6.

    Article  PubMed  Google Scholar 

  99. Kromer C, Lippert U, Schön MP, Mössner R. Treatment of pityriasis rubra pilaris: a case series of 28 patients. Eur J Dermatol. 2020;30:569–79.

    Article  CAS  PubMed  Google Scholar 

  100. Engelmann C, Elsner P, Miguel D. Treatment of pityriasis rubra pilaris type I: a systematic review. Eur J Dermatol. 2019;29:524–37.

    Article  CAS  PubMed  Google Scholar 

  101. Kromer C, Sabat R, Celis D, Mössner R. Systemic therapies of pityriasis rubra pilaris: a systematic review. J Dtsch Dermatol Ges. 2019;17:243–59.

    PubMed  Google Scholar 

  102. Zegpi-Trueba MS, Navajas-Galimany L, González S, Ramírez-Cornejo C. Acute postinfection pityriasis rubra pilaris: excellent response to emollients and topical corticosteroids. Actas Dermosifiliogr (Engl Ed). 2021;S1578–2190(21):00164–5.

    Google Scholar 

  103. Gregoriou S, Argyriou G, Christofidou E, Vranou A, Rigopoulos D. Treatment of pityriasis rubra pilaris with pimecrolimus cream 1%. J Drugs Dermatol. 2007;6:340–2.

    PubMed  Google Scholar 

  104. Van de Kerkhof PC, Steijlen PM. Topical treatment of pityriasis rubra pilaris with calcipotriol. Br J Dermatol. 1994;130:675–8.

    Article  PubMed  Google Scholar 

  105. Goldsmith LA, Weinrich AE, Shupack J. Pityriasis rubra pilaris response to 13-cis-retinoic acid (isotretinoin). J Am Acad Dermatol. 1982;6:710–5.

    Article  CAS  PubMed  Google Scholar 

  106. Ringin S, Baker CS, Foley P, Daniel BS. Pityriasis rubra pilaris treatment options: a retrospective case series from a tertiary hospital. Dermatol Ther. 2021;34:e15128.

  107. Gál B, Göblös A, Danis J, Farkas K, Sulák A, Varga E, et al. The management and genetic background of pityriasis rubra pilaris: a single-centre experience. J Eur Acad Dermatol Venereol. 2019;33:944–9.

    Article  PubMed  Google Scholar 

  108. Joshi TP, Wang HY, Athukuri P, Bohac S, Farr MA, Hinson D, et al. Biologic therapies for the management of cutaneous findings in genodermatoses: a review. Am J Clin Dermatol. 2022;23:673–88.

    Article  PubMed  Google Scholar 

  109. Napolitano M, Abeni D, Didona B. Biologics for pityriasis rubra pilaris treatment: a review of the literature. J Am Acad Dermatol. 2018;79:353-9.e11.

    Article  PubMed  Google Scholar 

  110. Maloney NJ, Kim MM, Nguyen KA, Hisaw LD, Worswick S. Patient experiences with biologics and apremilast in pityriasis rubra pilaris: a patient survey. Dermatol Ther. 2019;32: e13060.

    Article  PubMed  Google Scholar 

  111. Haynes D, Strunck JL, Topham CA, Ortega-Loayza AG, Kent G, Cassidy PB, et al. Evaluation of ixekizumab treatment for patients with pityriasis rubra pilaris: a single-arm trial. JAMA Dermatol. 2020;156:668–75.

    Article  PubMed  Google Scholar 

  112. Heibel MD, Heibel HD. Successful treatment of type I pityriasis rubra pilaris with ixekizumab. JAAD Case Rep. 2018;4:774–6.

    Article  PubMed  PubMed Central  Google Scholar 

  113. Hanfstingl K, Pekar-Lukacs A, Motz R, Guenova E, Hoetzenecker W. Successful treatment of pityriasis rubra pilaris with ixekizumab. Case Rep Dermatol. 2018;10:97–100.

    Article  PubMed  PubMed Central  Google Scholar 

  114. Bonomo L, Levitt JO. Secukinumab emerges as a rapidly effective therapy for pityriasis rubra pilaris. Cutis. 2018;101:367–9.

    PubMed  Google Scholar 

  115. Simpson K, Dolianitis C. A case of treatment-resistant pityriasis rubra pilaris responsive to secukinumab. Australas J Dermatol. 2021;62:441–2.

    Article  PubMed  Google Scholar 

  116. Papini M, Russo A, Natalini Y, Troiani L, Cassiani L. Secukinumab is an effective and safe treatment for refractory pityriasis rubra pilaris. Ital J Dermatol Venerol. 2021;156:501–2.

    PubMed  Google Scholar 

  117. Cole D, Mohammad T, Lim H. Rapid response of pityriasis rubra pilaris with psoriasis overlap to secukinumab. Br J Dermatol. 2019;181:1331–2.

    Article  CAS  PubMed  Google Scholar 

  118. Albela H, Lee WQ, Nordin SN, Gopinathan LP, Ramli MNA, Leong KF. Juvenile pityriasis rubra pilaris in a 4-year-old child treated successfully with secukinumab. Indian J Dermatol. 2022;67:601–3.

    PubMed  PubMed Central  Google Scholar 

  119. Xu Y-H, Dong D-D, Lin Y-F, Wang Q, Huang L-M, Shi J-Q. Successful treatment of severe pityriasis rubra pilaris with secukinumab in a 3-year-old boy. Clin Exp Dermatol. 2022;47:2043–5.

    Article  PubMed  Google Scholar 

  120. Wain T, Choy B, Satchell AC, Woods JA, Frew JW. Secukinumab in pityriasis rubra pilaris: a case series demonstrating variable response and the need for minimal clinical datasets. JAAD Case Rep. 2018;4:500–5.

    Article  PubMed  PubMed Central  Google Scholar 

  121. Matsuda T, Yamazaki F, Ueda-Hayakawa I, Kambe N, Okamoto H. Case of pityriasis rubra pilaris progressed to generalized erythroderma following blockade of interleukin-17A, but improved after blockade of interleukin-12/23 p40. J Dermatol. 2019;46:70–2.

    Article  CAS  PubMed  Google Scholar 

  122. Amat-Samaranch V, Cubiró X, Tubau C, Garcia-Melendo C, Puig L. Response of pityriasis rubra pilaris to brodalumab after primary failure to ustekinumab. Int J Dermatol. 2021;60:e112–4.

    Article  PubMed  Google Scholar 

  123. De Rosa A, Gambardella A, Licata G, Alfano R, Argenziano G. Successful treatment of pityriasis rubra pilaris with brodalumab. Australas J Dermatol. 2020;61:e249–51.

    PubMed  Google Scholar 

  124. De Felice C, Graceffa D, Morrone A, Bonifati C. Familial pityriasis rubra pilaris successfully treated with brodalumab. Int J Dermatol. 2020;59:885–7.

    Article  PubMed  Google Scholar 

  125. Nishimura M, Kondo M, Habe K, Hayashi A, Yamanaka K. Successful treatment with cyclosporine and guselkumab for pityriasis rubra pilaris. Clin Case Rep. 2022;10: e6413.

    Article  PubMed  PubMed Central  Google Scholar 

  126. Napolitano M, Lembo L, Fania L, Abeni D, Didona D, Didona B. Ustekinumab treatment of pityriasis rubra pilaris: a report of five cases. J Dermatol. 2018;45:202–6.

    Article  CAS  PubMed  Google Scholar 

  127. Bonomo L, Raja A, Tan K, Guttman-Yassky E. Successful treatment of juvenile pityriasis rubra pilaris with ustekinumab in a 7-year-old girl. JAAD Case Rep. 2018;4:206–10.

    Article  PubMed  PubMed Central  Google Scholar 

  128. Nielsen RM, Gram SB, Bygum A. Identification of a pathogenic CARD14 mutation in a 70-year-old woman with pityriasis rubra pilaris: when genetic diagnosis influences choice of treatment strategy. BMJ Case Rep. 2021;14: e235287.

    Article  PubMed  PubMed Central  Google Scholar 

  129. Pham JP, Allen N, Smith A. Efficacy of ustekinumab and guselkumab in treatment refractory pityriasis rubra pilaris: a case series. Australas J Dermatol. 2022;63:522–4.

    Article  PubMed  Google Scholar 

  130. Aragón-Miguel R, Prieto-Barrios M, Calleja-Algarra A, Velasco-Tamariz V, Andres-Lencina JJ, Ortiz-Romero P, et al. Refractory pityriasis rubra pilaris with good response after treatment with ustekinumab. J Dtsch Dermatol Ges. 2018;16:1022–5.

    Article  PubMed  Google Scholar 

  131. Ismail N, Callander J, Williams M, Anstey AV. Erythrodermic pityriasis rubra pilaris managed at home: intensive community care followed by ustekinumab. Clin Exp Dermatol. 2018;43:749–51.

    Article  CAS  PubMed  Google Scholar 

  132. Cook E, Tran KW, Kollipara S, Tarbox M, Akin R. A case of resistant pityriasis ribra pilaris responsive to combination acitrentin and ustekinumab. Dermatol Online J. 2020;26:13030/qt1712g0gm.

  133. DeBiasio C, Cyr J, Ayroud Y, Glassman SJ. A case of classic adult pityriasis rubra pilaris successfully treated with a combination of acitretin and ustekinumab: a case report. SAGE Open Med Case Rep. 2022;10:2050313X221093453.

  134. Katharina M, Sylvia S, Matthias B, Ulrich M, Martin L. Successful treatment of a child’s pityriasis rubra pilaris (PRP) with ustekinumab and acitretin. Pediatr Dermatol. 2022;39:659–61.

    Article  PubMed  PubMed Central  Google Scholar 

  135. Abdelnabi M, ElNawaa S, Benjanuwattra J, Elmassry M, Nair N. Ustekinumab-induced fatal acute heart failure in a young female: a case report. Methodist Debakey Cardiovasc J. 2022;18:54–8.

    Article  PubMed  PubMed Central  Google Scholar 

  136. Kalogeropoulos CI, Papathanasiou KA, Tsagkaraki I, Giannopoulos G, Bamias A, Boutati EI. A case of meningococcal and HSV-2 meningitis in a patient being treated with ustekinumab for pityriasis rubra pilaris. Eur J Case Rep Intern Med. 2020;7: 001615.

    PubMed  PubMed Central  Google Scholar 

  137. Nieto-Benito LM, Baniandrés-Rodríguez O, Moreno-Torres A, Hernández-Martín A, Torrelo-Fernández A, Campos-Domínguez M. Clinical response to ustekinumab in CARD14-associated papulosquamous eruption (CAPE) with a new missense mutation in CARD14: a case report and systematic review. J Eur Acad Dermatol Venereol. 2020;34:e728–30.

    Article  CAS  PubMed  Google Scholar 

  138. Nogueira M, Reis J, Abreu M, Coelho A, Reis CF, Machado S. A child with CARD14-associated papulosquamous eruption (CAPE) successfully treated with ustekinumab. Pediatr Dermatol. 2023;40:1104–6.

  139. Kiszewski AE, De Almeida HL. Successful treatment with ustekinumab in CARD14-associated papulosquamous eruption in a Brazilian child. Dermatol Ther. 2022;35: e15939.

    Article  CAS  PubMed  Google Scholar 

  140. Fouarge A-L, Cuvelier M, Roquet-Gravy C, de Montjoye L, Baeck M. Successful treatment of pityriasis rubra pilaris with risankizumab, a IL-23/p19 antagonist. J Eur Acad Dermatol Venereol. 2023;37:e106–9.

    Article  CAS  PubMed  Google Scholar 

  141. Kołt-Kamińska M, Osińska A, Kaznowska E, Reich A. Successful treatment of pityriasis rubra pilaris with risankizumab in children. Dermatol Ther (Heidelb). 2023;13:2431–41.

    Article  PubMed  PubMed Central  Google Scholar 

  142. Balestri R, Magnano M, Girardelli CR, Rech G. Is risankizumab effective in the treatment of pityriasis rubra pilaris? Dermatol Ther. 2021;34: e15112.

    Article  PubMed  Google Scholar 

  143. Kromer C, Schön MP, Mössner R. Treatment of pityriasis rubra pilaris with risankizumab in two cases. J Dtsch Dermatol Ges. 2021;19:1207–9.

    PubMed  Google Scholar 

  144. Ricar J, Cetkovska P. Successful treatment of refractory extensive pityriasis rubra pilaris with risankizumab. Br J Dermatol. 2021;184: e148.

    Article  CAS  PubMed  Google Scholar 

  145. Brocco E, Laffitte E. Risankizumab for pityriasis rubra pilaris. Clin Exp Dermatol. 2021;46:1322–4.

    Article  CAS  PubMed  Google Scholar 

  146. Duarte B, Paiva Lopes MJ. Response to: “Successful treatment of refractory extensive pityriasis rubra pilaris with risankizumab.” Br J Dermatol. 2021;185:235–6.

    Article  CAS  PubMed  Google Scholar 

  147. Nagai H, Jimbo H, Matsuura S, Tatsuoka S, Shiraki E, Nishigori C. Successful treatment of pityriasis rubra pilaris with guselkumab: serum CCL20 as a potential marker for the disease activity. Dermatol Ther. 2020;33: e14403.

    Article  CAS  PubMed  Google Scholar 

  148. Pilz AC, Seiringer P, Biedermann T, Eyerich K. Treatment of pityriasis rubra pilaris with guselkumab. JAMA Dermatol. 2019;155:1424–6.

    Article  PubMed  Google Scholar 

  149. Licata G, Gambardella A, Calabrese G, Pagliuca F, Alfano R, Argenziano G. Refractory type I pityriasis rubra pilaris treated with tildrakizumab. Clin Exp Dermatol. 2021;46:1594–5.

    Article  CAS  PubMed  Google Scholar 

  150. Zagarella SS, Jiang KW. Successful treatment of pityriasis rubra pilaris with tildrakizumab. Australas J Dermatol. 2022;63:120–1.

    Article  PubMed  Google Scholar 

  151. Lim JT, Tham SN. Pityriasis rubra pilaris in Singapore. Clin Exp Dermatol. 1991;16:181–4.

    Article  CAS  PubMed  Google Scholar 

  152. Dicken CH. Treatment of classic pityriasis rubra pilaris. J Am Acad Dermatol. 1994;31:997–9.

    Article  CAS  PubMed  Google Scholar 

  153. Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26:2016–29.

    Article  CAS  PubMed  Google Scholar 

  154. Molina-Figuera E, González-Cantero Á, Martínez-Lorenzo E, Sánchez-Moya A-I, García-Olmedo O, Gómez-Dorado B, et al. Successful treatment of refractory type 1 pityriasis rubra pilaris with apremilast. J Cutan Med Surg. 2018;22:104–5.

    Article  PubMed  Google Scholar 

  155. Inoue E, Arase N, Hanaoka Y, Tanemura A, Fujimoto M. The beneficial effect of a PDE4 inhibitor in a patient with juvenile-onset intractable pityriasis rubra pilaris without CARD14 mutation. Dermatol Ther. 2021;34: e14714.

    Article  CAS  PubMed  Google Scholar 

  156. Cho M, Honda T, Ueshima C, Kataoka T, Otsuka A, Kabashima K. A case of pityriasis rubra pilaris treated successfully with the phosphodiesterase-4 inhibitor apremilast. Acta Derm Venereol. 2018;98:975–6.

    Article  CAS  PubMed  Google Scholar 

  157. Pellonnet L, Beltzung F, Franck F, Rouanet J, D’incan M. A case of severe pityriasis rubra pilaris with a dramatic response to apremilast. Eur J Dermatol. 2018;28:128–9.

    Article  PubMed  Google Scholar 

  158. Chapman S, Adelman M, Sullivan A, Mancuso J, Lim HW. Apremilast-associated drug reaction with eosinophilia and systemic symptoms. JAAD Case Rep. 2020;6:302–4.

    Article  PubMed  PubMed Central  Google Scholar 

  159. Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76:736–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  160. Ying Y, Yu-Hua L, Xiao-Yan W, Su-Chun H. A case of pityriasis rubra pilaris treated with tofacitinib after failure with acitretin and ixekizumab. Australas J Dermatol. 2023;64:445–7.

  161. Saad M, Spurr A, Lipson J. Pityriasis rubra pilaris partially responsive to treatment with upadacitinib: a case report. SAGE Open Med Case Rep. 2023;11:2050313X231160927.

  162. Song EJ, Al-Saedy MA, Bouché N. Refractory pityriasis rubra pilaris treated with upadacitinib. JAAD Case Rep. 2023;35:112–4.

    Article  PubMed  PubMed Central  Google Scholar 

  163. Elmariah SB, Smith JS, Merola JF. JAK in the [black] box: a dermatology perspective on systemic JAK inhibitor safety. Am J Clin Dermatol. 2022;23:427–31.

    Article  PubMed  Google Scholar 

  164. Koch L, Schöffl C, Aberer W, Massone C. Methotrexate treatment for pityriasis rubra pilaris: a case series and literature review. Acta Derm Venereol. 2018;98:501–5.

    Article  CAS  PubMed  Google Scholar 

  165. Lee J, Iyengar S, Zinn Z. Pulsed dye laser as an adjunctive treatment for therapy-resistant pityriasis rubra pilaris. J Am Acad Dermatol. 2020;83:e391–2.

    Article  PubMed  PubMed Central  Google Scholar 

  166. Shao C, Velasco R, Greiling TM. The individual pityriasis rubra pilaris area and severity index (iPRPASI): validity, reliability, and responsiveness of a novel patient-reported severity tool. Arch Dermatol Res. 2023.

  167. Eastham AB, Femia AN, Qureshi A, Vleugels RA. Treatment options for pityriasis rubra pilaris including biologic agents: a retrospective analysis from an academic medical center. JAMA Dermatol. 2014;150:92–4.

    Article  PubMed  Google Scholar 

  168. Wetzig T, Sticherling M. Juvenile pityriasis rubra pilaris: successful treatment with ciclosporin. Br J Dermatol. 2003;149:202–3.

    Article  CAS  PubMed  Google Scholar 

  169. Amann PM, Susic M, Glüder F, Berger H, Krapf W, Löffler H. Alitretinoin (9-cis retinoic acid) is effective against pityriasis rubra pilaris: a retrospective clinical study. Acta Derm Venereol. 2015;95:329–31.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA

    Tejas P. Joshi

  2. Department of Dermatology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA

    Madeleine Duvic

Authors
  1. Tejas P. Joshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Madeleine Duvic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tejas P. Joshi.

Ethics declarations

Funding

No sources of funding were received for the preparation of this article.

Conflict of interest

Tejas P. Joshi and Madeleine Duvic have no conflicts of interest that are directly relevant to the content of this article.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Articles used in this review are available in the public domain.

Code availability

Not applicable.

Author contributions

TPJ conceived the idea for this review, performed the literature search, and wrote the first draft of the manuscript. MD provided expert guidance and critically revised the work. Both authors read and approved the final submitted version.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Joshi, T.P., Duvic, M. Pityriasis Rubra Pilaris: An Updated Review of Clinical Presentation, Etiopathogenesis, and Treatment Options. Am J Clin Dermatol 25, 243–259 (2024). https://doi.org/10.1007/s40257-023-00836-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-023-00836-x

Search

Navigation